Cardiovascular disease β€” encompassing coronary artery disease, heart failure, stroke, and peripheral arterial disease β€” remains the leading cause of death globally, responsible for approximately 18 million deaths per year. Clinical trials have produced transformative evidence over recent decades, validating statins, ACE inhibitors, beta-blockers, and more recently SGLT2 inhibitors and GLP-1 agonists as mortality-reducing therapies. Current research targets residual risk in optimally medicated patients.
Active trials include inclisiran (RNA interference to lower LDL twice yearly), zilebesiran for blood pressure reduction, colchicine for residual inflammatory risk in stable atherosclerosis, novel fibrin-targeting anticoagulants with lower bleeding risk, cardiac regeneration using stem cells or gene therapy, and AI-guided personalized risk models. Remote patient monitoring trials using wearable devices and implantable sensors are also reshaping outcomes research.
Many cardiovascular outcome trials enroll patients with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors; prior myocardial infarction, stroke, or peripheral artery disease are common eligibility requirements.
Frequently Asked Questions — atherosclerotic cardiovascular disease Clinical Trials
How many clinical trials are currently recruiting for atherosclerotic cardiovascular disease?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for atherosclerotic cardiovascular disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for atherosclerotic cardiovascular disease?
atherosclerotic cardiovascular disease research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a atherosclerotic cardiovascular disease clinical trial?
Eligibility criteria for atherosclerotic cardiovascular disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Novartis Pharmaceuticals 1 trial
Rajaie Cardiovascular Medical and Research Center 1 trial
China National Center for Cardiovascular Diseases 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: September 2026 ·
Data Methodology